Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
31,500
Employees31,500
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
31,500
Employees31,500

AMGN Key Statistics

Market cap
229.07B
Market cap229.07B
Price-Earnings ratio
26.32
Price-Earnings ratio26.32
Dividend yield
2.35%
Dividend yield2.35%
Average volume
3.50M
Average volume3.50M
High today
$426.59
High today$426.59
Low today
$421.19
Low today$421.19
Open price
$423.81
Open price$423.81
Volume
723.90K
Volume723.90K
52 Week high
$447.03
52 Week high$447.03
52 Week low
$274.02
52 Week low$274.02

Stock Snapshot

The current Amgen(AMGN) stock price is $423.71, with a market capitalization of 229.07B. The stock trades at a price-to-earnings (P/E) ratio of 26.32 and offers a dividend yield of 2.35%.

On 2026-09-30, Amgen(AMGN) stock traded between a low of $421.19 and a high of $426.59. Shares are currently priced at $423.71, which is +0.6% above the low and -0.7% below the high.

The Amgen(AMGN)'s current trading volume is 723.9K, compared to an average daily volume of 3.5M.

In the last year, Amgen(AMGN) shares hit a 52-week high of $447.03 and a 52-week low of $274.02.

In the last year, Amgen(AMGN) shares hit a 52-week high of $447.03 and a 52-week low of $274.02.

AMGN News

Simply Wall St 2h
Is Amgen Undervalued Following Its Phase 3 Sjögren's Disease Trial Update?

Amgen (AMGN) is back in focus after reporting positive topline Phase 3 data from its OASIZ 301 trial of dazodalibep in Sjögren's disease, which has sharpened at...

Is Amgen Undervalued Following Its Phase 3 Sjögren's Disease Trial Update?
TipRanks 1d
Amgen price target raised to $500 from $450 at Scotiabank

Scotiabank analyst Louise Chen raised the firm’s price target on Amgen (AMGN) to $500 from $450 and keeps an Outperform rating on the shares. The firm notes Amg...

24/7 Wall St. 1d
Why Amgen's 6% Dividend Raise Masks a Tougher Road Ahead

Investing Why Amgen’s 6% Dividend Raise Masks a Tougher Road Ahead Amgen just handed income investors another dividend raise, but a mountain of acquisition debt...

Why Amgen's 6% Dividend Raise Masks a Tougher Road Ahead

Analyst ratings

51%

of 37 ratings
Buy
32.4%
Hold
51.4%
Sell
16.2%

More AMGN News

Simply Wall St 5d
How Phase 3 Sjögren’s Results At Amgen Has Changed Its Investment Story

Amgen reported positive topline Phase 3 OASIZ 301 data for dazodalibep in adults with moderate-to-severe systemic Sjögren’s disease, with statistically signific...

How Phase 3 Sjögren’s Results At Amgen Has Changed Its Investment Story
Zacks 5d
Amgen Rises Higher Than Market: Key Facts

In the latest close session, Amgen (AMGN Quick QuoteAMGN - Free Report) was up +2.11% at $414.61. The stock's change was more than the S&P 500's daily gai...

Amgen Rises Higher Than Market: Key Facts
24/7 Wall St. 6d
How a Roth IRA Can Keep Thousands More of Your DJIA Dividend Income Compounding

Investing How a Roth IRA Can Keep Thousands More of Your DJIA Dividend Income Compounding Holding blue-chip Dow dividend payers in a taxable account quietly han...

How a Roth IRA Can Keep Thousands More of Your DJIA Dividend Income Compounding
Simply Wall St 6d
Amgen Stock Could Be 40% Undervalued On Phase 3 Sjögren’s Data

has delivered a strong run over the past several years and now trades near US$406, which naturally raises the question of whether that price is fully supported...

Amgen Stock Could Be 40% Undervalued On Phase 3 Sjögren’s Data

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.